您的位置: 首页 > 农业专利 > 详情页

Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
专利权人:
TAKEDA GMBH
发明人:
WOLLIN, STEFAN-LUTZ,WOHLSEN, ANDREA,BRAUN, CLEMENS,MARX, DEGENHARD
申请号:
NZ59436907
公开号:
NZ594369A
申请日:
2007.07.03
申请国别(地区):
NZ
年份:
2013
代理人:
摘要:
594369 Disclosed is a pharmaceutical composition and a combination product comprising Roflumilast also known as 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; Rosuvastatin also known as (3R,5R)-7-{ 4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl} -3,5-dihydroxyheptanoic acid; and a pharmaceutically acceptable auxiliary. In the combination product the two actives are adapted for simultaneous or sequential administration. Also disclosed is the process for making the composition and the use of the composition for the manufacture of a medicament for the treatment of an inflammatory pulmonary disease.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充